

Edgar Filing: NOVAMED INC - Form 10QSB

NOVAMED INC
Form 10QSB
June 07, 2002

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

- Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2002.
- Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____.

Commission file number: 0-26927

NOVAMED, INC.
(Exact name of small business issuer as specified in its charter)

Nevada -----	77-0443643 -----
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1403 East 900 South, Salt Lake City, Utah 84105
(Address of principal executive office) (Zip Code)

(801) 582 9609
(Issuer's telephone number)

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes XX -----	No -----
-----------------	-------------

The number of outstanding shares of the issuer's common stock, \$0.001 par value (the only class of voting stock), as of May 31, 2002 was 869,858

TABLE OF CONTENTS

Edgar Filing: NOVAMED INC - Form 10QSB

PART I

ITEM 1. FINANCIAL STATEMENTS.....3
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.....5

PART II

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.....7
SIGNATURES.....8
INDEX TO EXHIBITS.....9

[THIS SPACE HAS BEEN INTENTIONALLY LEFT BLANK]

ITEM 1. FINANCIAL STATEMENTS

As used herein, the term "Company" refers to NovaMed, Inc., a Nevada corporation, and its subsidiaries and predecessors unless otherwise indicated. Consolidated, unaudited, condensed interim financial statements including a balance sheet for the Company as of the quarter ended March 31, 2002, and statements of operations, and statements of cash flows for the interim period up to the date of such balance sheet and the comparable period of the preceding year are attached hereto as Pages F-1 through F-4 and are incorporated herein by this reference.

Edgar Filing: NOVAMED INC - Form 10QSB

[THIS SPACE HAS BEEN LEFT BLANK INTENTIONALLY.]

3

NOVAMED, INC.
Index to Consolidated Financial Statements

	Page
Consolidated balance sheet at March 31, 2002 (unaudited)	F-1
Consolidated statement of operations for three months ended March 31, 2002 and 2001 (unaudited)	F-2
Consolidated statement of cash flows for the three months ended March 31, 2002 and 2001 (unaudited)	F-3
Notes to consolidated financial statements	F-4

Edgar Filing: NOVAMED INC - Form 10QSB

NOVAMED, INC.
Consolidated Balance Sheet

March 31, 2002 (Unaudited)

Assets	
Current assets:	
Cash	\$ 19,982

Current assets	19,982
Property and equipment, net	28,590

Total assets	\$ 48,572

Liabilities and Stockholders' Equity (Deficit)	
Current liabilities:	
Accounts payable and accrued liabilities	\$ 144,357
Accrued royalty payments	42,000
Accrued payroll taxes and related items	5,144
Notes payable	20,000

Total current liabilities	211,501

Stockholders' equity (deficit):	
Common stock, par value \$.001 per share; authorized 50,000,000 shares, issued and outstanding 869,858 shares	870
Additional paid-in capital	6,281,317
Accumulated deficit	(6,445,116)

Edgar Filing: NOVAMED INC - Form 10QSB

Total stockholders' equity (deficit)	(162,929)
Total liabilities and stockholders' equity (deficit)	\$ 48,572

F-1

NOVAMED, INC.
Consolidated Statement of Operations

	Three Months Ended March 31, (Unaudited)		Cumulative Amounts since inception of Development Stage (January 1, 2001)
	2002	2001	
Net sales	\$ -	\$ -	\$ -
Costs and expenses:			
Cost of sales/manufacturing	330	8,306	33,636
Selling, general and administrative	10,607	340,398	10,607
Research and development	-	-	-
	10,937	348,704	10,937
Loss before income taxes and extraordinary items	(10,937)	(348,704)	(10,937)
Extraordinary items			
Gain on settlement of accrued interest	6,761	-	6,761
Loss before income taxes	(4,176)	(348,704)	(4,176)
Provision for income taxes	-	-	-

Edgar Filing: NOVAMED INC - Form 10QSB

Net loss	\$ (4,176)	\$ (348,704)	\$ (4,176)
Loss per common share - basic and diluted	\$ 0.00	\$ (0.40)	
Weighted average common shares - basic and diluted	869,858	869,858	

F-2

NOVAMED, INC.
Consolidated Statement of Cash Flows

	Three Months Ended March 31, (Unaudited)		Cumulati Amount since inc of Develo Stage (January 1,
	2002	2001	
Cash flows from operating activities:			
Net loss	\$ (4,176)	\$ (348,704)	\$ (4,176)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation	4,481	-	4,481
Gain on settlement of accrued interest	(6,761)	-	(6,761)
Stock issued for royalties and license fees	-	262,500	
(Increase) decrease in:			
Receivables	15,000	-	15,000
Increase (decrease) in:			
Accounts payable and accrued liabilities	1,404	(16,732)	1,404
Net cash provided by (used in) operating activities	9,948	(102,936)	9,948
Cash flows from investing activities:	-	-	

Edgar Filing: NOVAMED INC - Form 10QSB

Cash flows from financing activities:			
Issuance of convertible debentures	-	100,000	
	-----	-----	-----
Net cash provided by financing activities	-	100,000	
	-----	-----	-----
Net increase (decrease) in cash	9,948	(2,936)	9,94
Cash, beginning of period	10,034	11,779	10,03
	-----	-----	-----
Cash, end of period	\$ 19,982	\$ 8,843	\$ 19,98
	-----	-----	-----

F-3

NOVAMED, INC.
Notes to Consolidated Financial Statements

-
- (1) The unaudited consolidated financial statements include the accounts of NovaMed, Inc. and NovaMed Manufacturing, Inc. and include all adjustments (consisting of normal recurring items) which are, in the opinion of management, necessary to present fairly the financial position as of March 31, 2002, and the results of operations and cash flows for the three months ended March 31, 2002 and 2001. The results of operations and cash flows for the three months March 31, 2002 are not necessarily indicative of the results to be expected for the entire year.
- (2) Loss per share is based on the weighted average number of shares outstanding at March 31, 2002 and 2001, respectively.
- (3) On May 7, 2002, subsequent to the end of the period, Novamed effected a 1 for 50 reverse stock split. The number of shares issued and outstanding before the split was 43,486,464 shares and after the split, taking into account slight rounding differences, the number outstanding was 869,858 shares. Presented financial statements reflect retroactive adjustments for the reverse split.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The Company is a medical device holding company that developed, manufactured, and marketed hydrogel and saline filled breast implant products that were used in primary augmentations, revisions, or reconstructive procedures.

The Company manufactured and marketed two different pre-filled single lumen mammary prostheses (breast implants), the NOVAGOLDTM and the NOVASALINETM. These products were designed to address the safety concerns associated with silicone gel-filled implants, as voiced by the FDA's decision in April of 1992 which mandated that silicone gel implants would thereafter only be available under controlled clinical studies. Both products were used for routine cosmetic breast augmentation and for breast reconstruction following either subcutaneous or modified radical mastectomy. The Company has realized no sales revenues since October of 2000, due to the prohibition placed on the sale of the Company's products and the default on the License Agreement related to the Company's use of patented technology in its products.

Since the Company was not able to generate any revenues in 2001 it is now considering the viability of continuing in the business of developing, manufacturing and marketing breast implant products. While considering the viability of its breast implant business, management is also considering other business opportunities either through merger or acquisition that might create value for our shareholders.

Results of Operations

Net sales were \$0 for the three months ended March 31, 2002, compared to \$0 for the comparable period in 2001. The lack of sales was due to having no significant operations.

Cost of Sales

Cost of sales were \$330 for the three months ended on March 31, 2002, compared to \$8,036 for the comparable period in 2001, a decrease of 95% for the three month period ended March 31, 2001. The decrease in cost of sales was a result of no significant operations in the period.

Losses

The Company recorded net losses of \$4,176 for the three months ended March 31, 2002, compared to \$348,704 for the comparable period in 2001, an decrease of 99% for the three month period ended March 31, 2001. The decrease was the result of no significant operations coupled with a lack of expenses relating to the

Edgar Filing: NOVAMED INC - Form 10QSB

elimination of the German subsidiary and buyout of the license fees and royalties relating to that subsidiary.

The Company expects to continue to incur losses at least through fiscal 2002 and there can be no assurance that the Company will achieve or maintain profitability or that its revenue growth can be sustained in the future.

Expenses

Selling, general and administrative expenses were \$10,607 for the three months ended March 31, 2002 as compared to \$340,398 for the comparable period in 2001, a decrease of 97% from the three month period ending March 31, 2001. The decrease in selling, general and administrative costs was the result of no significant operations and the lack of costs that were associated with the operation of the Company's former German subsidiary.

5

Capital Expenditures

The Company expended no amounts on capital expenditures for the quarterly period ending March 31, 2002.

Capital Resources and Liquidity

The Company had current assets of \$19,982 and total assets of \$48,572 as of the quarterly period ending March 31, 2002. These assets consist of cash on hand of \$19,982 and equipment, net of depreciation, of \$25,590. Stockholders' deficit in the Company was \$162,929 at March 31, 2002.

Cash flow provided by operating activities was \$9,948 for the three months ending March 31, 2002 compared to cash flow used in operating activities of \$102,936 for three months ended March 31, 2001. The increase in cash flows from operations for the three months ended March 31, 2002, was the result of a significant drop in losses, mentioned above, coupled with the receipt of receivables and a lack of royalty payments.

The Company has a working capital deficit of \$191,519 on March 31, 2002. The Company's plan for liquidity resources include delaying payments on accounts payable and debts by renegotiated terms, obtaining equity or debt financing and selling assets of the Company. Management can provide no assurance that these efforts will be successful. The Company believes that its owners, affiliates and consultants will provide sufficient additional capital to continue operations through debt or equity financing, though the Company can provide no assurance that this assumption can be realized if necessary.

The Company has no intention of conducting any research or development until such time as resolution is reached in connection with the viability of its breast implant business or another business opportunity is acquired through merger or acquisition.

The Company currently has no employees and does not believe that employees will be added until such time as funding is obtained for its breast implant business or another business opportunity is pursued.

Edgar Filing: NOVAMED INC - Form 10QSB

The Company's auditors have expressed an opinion as to the Company's ability to continue as a going concern on their report dated April 10, 2002, for the period ended December 31, 2001, as a result of accumulated deficits. The Company's ability to continue as a going concern is subject to the ability of the Company to obtain a profit and /or obtaining the necessary funding from outside sources. Management's plan to address the Company's ability to continue as a going concern, includes: (1) obtaining funding from private placement sources; (2) obtaining additional funding from the sale of the Company's securities; (3) establishing revenues from a suitable business opportunity; (4) obtaining loans and grants from various financial institutions where possible. Although management believes that it will be able to obtain the necessary funding to allow the Company to remain a going concern through the methods discussed above, there can be no assurances that such methods will prove successful.

6

PART II

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

- (a) Exhibits Exhibits required to be attached by Item 601 of Regulation S-B are listed in the Index to Exhibits on page 8 of this Form 10-QSB, and are incorporated herein by this reference.
- (b) Reports on Form 8-K. The Company filed the following report on Form 8-K during the period ended March 31, 2002.
 - 1. The Company reported on March 1, 2002 on Form 8-K that it had entered into a Stock Sale Agreement ("Agreement") for the sale of 450,000 shares of Cryogenic Laboratories Incorporated to Mr. John Olson, in exchange for \$25,000 and Mr. Olson's assumption of liabilities, including principal and interest amounting to over \$200,000 in the form of debentures. On February 27, 2002, the Company acknowledged the receipt of the \$25,000 and the written agreement of the debenture holders to the assignment of all liabilities attached thereto.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 6th day of June 2002.

NOVAMED, INC.

/s/ Ruairidh Campbell

Ruairidh Campbell
President, Chief Executive Officer and Director

June 6, 2002

INDEX TO EXHIBITS

EXHIBIT NO.	PAGE NO.	DESCRIPTION
3(i)	*	Articles of Incorporation of the Company formerly known as Conceptual Technologies, Inc., a Nevada corporation dated November 26, 1996. (Incorporated herein by reference to the Company's

Edgar Filing: NOVAMED INC - Form 10QSB

Form 10SB/A-1 filed on November 2, 1999 as exhibit 2(i)).

3(ii)

*

By-laws of the Company adopted on November 12, 1996. (Incorporated herein by reference to the Company's Form 10SB/A-1 filed on as exhibit 2(iv)).